IconicAlpha
← Back to the wall
AbbVie Inc.

AbbVie Inc.

ABBV · Healthcare · Biotechnology

Market cap
$506.7B
Price
$286.74
Daily change
+0.39%
Rank
#18

Updated 6h ago · data delayed ≥15 min

IconicScore

Proprietary
72/ 100
Scale66
Momentum52
Sector leadership97
Brand visibility85

Ranked #21 of 500 by Iconic Score · #3 of 59in its sector. IconicAlpha’s proprietary brand-intelligence metric — a multi-model blend of scale, market attention, category leadership, and AI-analyzed brand visibility.

Score trend · 88d+5 pts
Free · every trading day, 7 AM ET

Get the free morning email

The biggest IconicScore™ gainer and loser, plus the strongest and weakest sectors, in your inbox before the open. See a sample →

Price performance

Export history · Analyst
Price$286.74+45.0%
$289$198
Apr 26Oct 26
IconicScore vs. price

This insight is part of the Analyst tier — unlock the IconicScore vs. price overlay, side-by-side comparison, and CSV export.

Upgrade to Analyst
Sector benchmark

This is part of the Enterprise tier — benchmark your IconicScore against sector peers, claim your profile, and manage how your brand appears on the wall.

Upgrade to Enterprise

Iconic Profile

AbbVie Inc (ABBV) is a global biopharmaceutical company specializing in the discovery, development, and commercialization of innovative therapies for complex diseases. With a market capitalization of $438.3 billion, AbbVie holds a strong position in the biotechnology sector, driven by its robust portfolio of immunology, oncology, and neuroscience products, including the blockbuster drug Humira. The company's commitment to research and development, alongside strategic acquisitions, enhances its pipeline and market presence. AbbVie's focus on addressing unmet medical needs and improving patient outcomes underscores its significance in the healthcare landscape, making it a key player in the ongoing evolution of biopharmaceutical solutions.

IconicOracleAI™ Brief

AbbVie Inc's Iconic Score of 69 reflects a solid brand presence, bolstered by a high brand-visibility signal of 85/100, indicating strong recognition in the market. Recent discussions comparing AbbVie to competitors like AstraZeneca and Bristol Myers Squibb highlight its competitive positioning in earnings growth narratives. Additionally, advancements in Allergan Aesthetics, particularly around the HArmonyCa™ evidence presented at AMWC Dubai, contribute positively to its brand perception, showcasing innovation in its product offerings.

AI-generated explanation of current score drivers. Not investment advice.

Visit website ↗Compare ⇄Claim this profile

Enterprise tier: claim your logo to manage how your brand is represented.